The company's cash runway is tight and the recent $3.75M offering provides limited breathing room while diluting existing holders. GLIX1 pipeline progress is the key catalyst — watch for Phase 1 dose escalation updates and the planned ovarian cancer arm expansion. The CheMo4METPANC PDAC trial interim analysis expected in 2026 could be a major inflection point. Monitor for further financing needs given the going concern disclosure.
Price Chart
Executive Summary
BioLineRx reported Q2 2026 results with net loss widening to $4.3M (vs $3.9M a year ago) and H1 loss of $6.9M vs income of $1.2M in H1 2025. Cash stands at $13.1M with runway into H1 2027, but a going concern uncertainty is disclosed. GLIX1 Phase 1/2a in GBM is advancing (second cohort dosing, third expected September) with promising preclinical data. A dilutive $3.75M offering at $2.78/ADS closed on August 31, 2026.
Key Facts
- Net loss H1 2026 was $6.9M vs income of $1.2M in H1 2025; operating loss widened to $6.6M from $4.7M
- Cash, cash equivalents and short-term deposits totaled $13.1M as of June 30, 2026; management expects runway into H1 2027
- Going concern uncertainty disclosed — accumulated deficit reached $406M through June 30, 2026
- On August 27, 2026, entered into a definitive agreement for a $3.75M registered direct offering at $2.78 per ADS/pre-funded warrant, closed August 31
- GLIX1 Phase 1/2a in GBM: second of five cohorts dosing; third cohort expected to start in September 2026
- Preclinical data showed GLIX1 anti-tumor activity in TMZ-resistant GBM models and synergy with PARP inhibitors in HR-proficient ovarian cancer
- APHEXDA (motixafortide) Q2 2026 sales were $1.6M, generating $0.3M in royalty revenue for BioLineRx
- R&D expenses rose 26.5% to $2.9M in Q2 2026, driven by GLIX1 development
Financial Impact
Net loss of $4.3M in Q2 2026 and $6.9M in H1 2026; cash burn of $5.5M from operations in H1 2026; $3.75M dilutive offering at $2.78/ADS closed post-quarter
Risk Factors
- Going concern risk — cash runway only into H1 2027 with no guarantee of additional financing
- Dilution from recent $3.75M offering and potential future equity raises
- Early-stage GLIX1 pipeline — Phase 1/2a data is preliminary and may not translate to later-stage success
- Geopolitical risk from ongoing conflict in Israel where headquarters and key operations are located
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-004331 |
| Exhibit: exhibit_1.htm | 0001178913-26-004331 |
| Exhibit: exhibit_3.htm | 0001178913-26-004331 |
| Document: zk2635990.htm | 0001178913-26-004331 |
| Document: 0001178913-26-004331-index-headers.html | 0001178913-26-004331 |
| Document: 0001178913-26-004331-index.html | 0001178913-26-004331 |
| Document: 0001178913-26-004331.txt | 0001178913-26-004331 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 6-K | $2.04 | awaiting T+20 | — | $2.03 (−0.49%) |
Oct 5, 2026 22d ago | EFFECT | $2.32 | awaiting T+20 | — | $2.03 (+12.50%) |
Sep 25, 2026 4w ago | F-1 | $2.43 $2.00 | ▼ −17.70% | ▼ −17.66% | $2.03 (−16.46%) |
Sep 10, 2026 6w ago | 6-K | $2.57 $2.21 | ▼ −13.99% | ▼ −16.12% | $2.03 (−21.00%) |
Aug 31, 2026 8w ago | 424B5 | $2.80 $2.36 | ▲ +15.71% | ▲ +15.34% | $2.03 (+27.50%) |
Aug 31, 2026 8w ago | 6-K | $2.80 $2.36 | ▲ +15.71% | ▲ +15.34% | $2.03 (+27.50%) |
Aug 31, 2026 8w ago | 6-K | $2.80 $2.36 | ▲ +15.71% | ▲ +15.34% | $2.03 (+27.50%) |
Aug 28, 2026 8w ago | 6-K | $2.60 $2.43 | ▲ +6.54% | ▲ +6.80% | $2.03 (+21.92%) |
Aug 28, 2026 8w ago | Press Release | $2.60 $2.43 | ▲ +6.54% | ▲ +6.80% | $2.03 (+21.92%) |
Jul 8, 2026 15w ago | 6-K | $3.01 $2.72 | ▼ −9.73% | ▼ −13.01% | $2.03 (−32.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers